On this episode of TMU we're diving deep into the rapidly evolving landscape of prostate cancer diagnosis and treatment with special guest, Dr. Adam Cole, a board-certified pathologist. Dr. Cole will discuss the traditional Gleason grading system, the limitations of pathology, and how incorporating genetic markers can improve patient outcomes. Dr. Cole will touch on the importance of genetic testing in guiding treatment plans, and the potential use of artificial intelligence shaping the future of pathology.